News & Updates
Filter by Specialty:
First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma
22 Dec 2023
byStephen Padilla
First-line combination immuno-oncology therapy (IO) with ipilimumab and nivolumab provides beneficial effects and has an acceptable safety profile in patients with metastatic renal cell carcinoma, as shown in a Japan study presented at ESMO Asia 2023.
First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma
22 Dec 2023Faecal microbiota spores deliver benefit in older patients with C. diff recurrence
22 Dec 2023
byAudrey Abella
In an integrated analysis of two phase III ECOSPOR trials presented at AIBD 2023, faecal microbiota spores (ie, live-brpk) demonstrated favourable safety and efficacy signals for the treatment of recurrent Clostridioides (C.) difficile infection (CDI) in older individuals.
Faecal microbiota spores deliver benefit in older patients with C. diff recurrence
22 Dec 2023Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
21 Dec 2023
byJairia Dela Cruz
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.